COMBINATION OF HETEROCYCLIC COMPOUNDS: AS ANTICANCER AGENTS

Abstract

Benzimidazole and Pyrazole both are heterocyclic aromatic organic compounds. These two heterocyclic compounds are occupied prominent place among various classes of aromatic organic compounds. Heterocyclic compounds having a variety of therapeutic uses, including antitumor, antifungal, antiparasitic, analgesics, antiviral, antihistamine, as well as use in cardiovascular disease, neurology, endocrinology, and ophthalmology. Both Benzimidazole and Pyrazole are also effective in anticancer. All the newly synthesized heterocyclic compounds were screened for the in-vivo cytotoxic activity by XTT assay methods using various cell lines like VERO, NCI, MDA-MB-453 and MDA-MB-468 using doxorubicin as standard drugs for comparison of results. Aims: To design and identify new heterocyclic compounds to potent anticancer activity. Methods: XTT assay method. Results: By using different cell lines for 10 compounds we find positive results for one or two compounds. From the discussion, we conclude that compound which contain o-nitrobenzene as attachment gives better anticancer activity in all cell lines, whereas compound contain p-flourobenzene as attachment gives better anticancer activity in cell line like NCI, MDA-MB-453 and MDA-MB-468. The compound contains m-nitrobenzene gives positive results in VERO cell line.